
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/base_style-CPPDhfna.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-BepKMsUl.js"></script>

  <link rel="stylesheet" href="/static/assets/article_style-DUfI1jZp.css" />
<link rel="stylesheet" href="/static/assets/style-BOrsu84o.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-D3wJHomh.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="CFBE25C5930B2A130025C5000D3BA08C.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="orphjrdis">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12181874/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Orphanet Journal of Rare Diseases">
<meta name="citation_title" content="Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database">
<meta name="citation_author" content="Luyao Xu">
<meta name="citation_author_institution" content="Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China">
<meta name="citation_author" content="Kaili Mao">
<meta name="citation_author_institution" content="Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China">
<meta name="citation_author" content="Songyang Zhong">
<meta name="citation_author_institution" content="Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China">
<meta name="citation_author" content="Huayu Sun">
<meta name="citation_author_institution" content="Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China">
<meta name="citation_author" content="Hongliang Zheng">
<meta name="citation_author_institution" content="Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China">
<meta name="citation_author" content="Zhenling Fu">
<meta name="citation_author_institution" content="Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China">
<meta name="citation_publication_date" content="2025 Jun 20">
<meta name="citation_volume" content="20">
<meta name="citation_firstpage" content="315">
<meta name="citation_doi" content="10.1186/s13023-025-03864-4">
<meta name="citation_pmid" content="40542371">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12181874/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12181874/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12181874/pdf/13023_2025_Article_3864.pdf">
<meta name="description" content="This research aimed to assess the safety of pegvaliase through analyzed the data from the FAERS database, thus providing a theoretical foundation for the rational and safe application of pegvaliase in clinical settings. Pegvaliase-associated adverse ...">
<meta name="og:title" content="Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="This research aimed to assess the safety of pegvaliase through analyzed the data from the FAERS database, thus providing a theoretical foundation for the rational and safe application of pegvaliase in clinical settings. Pegvaliase-associated adverse ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12181874/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12181874">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s13023-025-03864-4"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/13023_2025_Article_3864.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12181874%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12181874/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12181874/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12181874/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-orphjrdis.png" alt="Orphanet Journal of Rare Diseases logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Orphanet Journal of Rare Diseases" title="Link to Orphanet Journal of Rare Diseases" shape="default" href="https://ojrd.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Orphanet J Rare Dis</button></div>. 2025 Jun 20;20:315. doi: <a href="https://doi.org/10.1186/s13023-025-03864-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s13023-025-03864-4</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Orphanet%20J%20Rare%20Dis%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Orphanet%20J%20Rare%20Dis%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Orphanet%20J%20Rare%20Dis%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Orphanet%20J%20Rare%20Dis%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Luyao Xu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Luyao Xu</span></h3>
<div class="p">
<sup>1</sup>Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Luyao Xu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mao%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Kaili Mao</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Kaili Mao</span></h3>
<div class="p">
<sup>1</sup>Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mao%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kaili Mao</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhong%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Songyang Zhong</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Songyang Zhong</span></h3>
<div class="p">
<sup>1</sup>Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhong%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Songyang Zhong</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Huayu Sun</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Huayu Sun</span></h3>
<div class="p">
<sup>1</sup>Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Huayu Sun</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zheng%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Hongliang Zheng</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Hongliang Zheng</span></h3>
<div class="p">
<sup>1</sup>Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zheng%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hongliang Zheng</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Zhenling Fu</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Zhenling Fu</span></h3>
<div class="p">
<sup>1</sup>Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhenling Fu</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, No.100 Minjiang Road, Kecheng District, Quzhou, 324000 Zhejiang China </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jan 8; Accepted 2025 Jun 15; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (<a href="https://creativecommons.org/publicdomain/zero/1.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12181874  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40542371/" class="usa-link">40542371</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Objective</h3>
<p id="Par1">This research aimed to assess the safety of pegvaliase through analyzed the data from the FAERS database, thus providing a theoretical foundation for the rational and safe application of pegvaliase in clinical settings.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">Pegvaliase-associated adverse event reports were searched in FAERS database from the 2018 Q3 to 2023 Q2. These data were further mined through Four different algorithms, including ROR, PRR, BCPNN, and EBGM.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">A total of 5,076 AEs reports were obtained from the FAERS database. At the PTs level, it was discovered that AE reports associated with pegvaliase as the primary suspect were connected to the 27 SOCs. Among these PTs, 83 signals in total were found, and each of them concurrently complied with the four algorithms. Further, we ranked PTs first for arthralgia in order of frequency and first for decreased amino acid levels in order of signal intensity. The median time to onset of adverse reactions was 15 days.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">We mined and analyzed the AE signals of pegvaliase based on the FAERS database, it turned out that they were generally consistent with the drug inserts and clinical trial results. However, potential new AE signals were revealed, providing a basis for the identification of adverse reactions in the clinical setting.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s13023-025-03864-4.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Pegvaliase, Pharmacovigilance, Data mining, FAERS database, Adverse event</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par5">Phenylketonuria (PKU) is an autosomal recessive disorder caused by a deficiency of the phenyalanine hydroxylase (PAH), which leads to elevated levels of phenylalanine (Phe) and affects approximately 1 in 24,000 people, with an estimated 0.45 million affected individuals worldwide [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Hyperphenylalaninemia (HPA), characterized by elevated levels of Phe in the blood and cerebrospinal fluid, is caused by dysregulated Phe metabolism. Tetrahydrobiopterin (BH4), a pivotal cofactor in Phe metabolism, is essential for the enzymatic breakdown of Phe [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. PKU, the main type of HPA, has phe levels exceeding 360 µmol/L [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. The absence of PAH eventually causes elevated levels of Phe in the blood and brain, which can cause intellectual incapacity, epilepsy, seizures, microcephaly, delayed speech, psychotic movement disorders, eczema, generalized hypopigmentation of skin (including eyes and hair), and a musty sweat odor if PKU is left untreated [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>–<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. Most cases of PKU are detected shortly through newborn screening (NBS) shortly after birth. Early and sustained management of Phe levels improves health-related quality of life in these patients [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. As a result, severe PKU symptoms and indicators are uncommon [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Phe levels should be kept between 120 and 360 µmol/L throughout life, according to American College of Medical Genetics and Genomics (ACMG) standards, for the best possible outcome [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. The most common PKU treatment strategy, known as a restricted Phe diet, entails cutting back on natural protein sources and replacing them with low- or Phe-free alternatives as well as customized low-protein meals (SLPFs). However, Long-term adherence to the restrictive diet is challenging for patients [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]. Sapropterin was approved by Food and Drug Administration (FDA) on December 13, 2007, and was the first pharmacologic therapy for treatment of PKU. Sapropterin is used in conjunction with a phenylalanine-restricted diet. The efficacy of sapropterin depends on the presence of residual PAH enzyme activity, which works for approximately 25–50% of PKU patients [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. The new therapy option of Pegvaliase is of particular importance as it has brought new hope to patients who do not respond to dietary restrictions and sapropterin, filling a critical gap in treatment options for this patient population.</p>
<p id="Par6">Pegvaliase (Palynziq<sup>®</sup>, BioMarin Pharmaceutical Inc., Novato, CA, USA) was authorized as an enzyme-substitution therapy for adults (US) or patients aged ≥ 16 years (Europe) with PKU and uncontrolled blood Phe concentrations &gt; 600µmol/L on current management [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>, <a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. According to Janet Thomas et al., Of the 261 adult participants who received an average of 36.6 months of pegavarase treatment, 71.3%, 65.1%, and 59.4% achieved clinically significant blood Phe levels of ≤ 600, ≤360, and ≤ 120 µmol/L, respectively [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>, <a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Phase 1 to phase 3 clinical trial data indicates significant drops in blood phenylalanine concentrations and amelioration of inattention and mood symptoms when pegvaliase is used [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>–<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. In the Phase 3 PRISM-1 and PRISM-2 clinical trials [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>, <a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>], pegvaliase-induced blood Phe reductions were clinically meaningful and statistically significant versus placebo and were sustained at a population level at 24 months of follow-up. As pegvaliase becomes more increasingly used, the attention to its associated adverse reactions and drug-related adverse events, such as anaphylaxis, injection site response, and arthralgia, has also increased. To guarantee patient safety and maximize treatment results, it is crucial to focus on these adverse occurrences. It allows the creation of monitoring and preventive measures, helps healthcare providers manage medications, and enables individualized treatment programs. In the end, these initiatives help to improve patient outcomes, optimize treatment plans, and advance the medical industry.</p>
<p id="Par7">The FDA Adverse Event Reporting System (FAERS) database is a publicly available, online-accessible database of reports from the FDA’s self-reporting system. It has been widely used in the research field of pharmacovigilance [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>, <a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. This research aimed to assess the safety of pegvaliase through the analysis of data from FAERS using data mining techniques, thus providing a point of reference for clinical monitoring and risk identification.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Data sources and mining</h3>
<p id="Par8">We launched a retrospective pharmacovigilance study on adverse events associated with pegvaliase. We extract all pegvaliase-related adverse events (AEs) from 2018 Q3 to 2023 Q2 from the FAERS database. A flow diagram of database mining was showed in Fig. <a href="#Fig1" class="usa-link">1</a>. During the study period, a total of 19,806,910 reports of pegvaliase were obtained from the FAERS database. Duplicated records were deleted according to the deduplication process recommended by FDA. We selected PRIMARYID, CASEID, and FDA_DT fields in the demographics table and sorted them in the order of CASEID, FDA_DT, and PRIMARYID. For reports with the same CASEID, we retained the one with the largest FDA_DT value. For reports with the same CASEID and FDA_DT, we reserved the one with the largest PRIMARYID value. Drugs were categorized into four patterns: PS (primary suspect), SS (secondary suspect), C (concomitant), and I (interacting). In this study, we only analyzed monotherapy and incorporated the reports only identified as the PS drug leading to AEs to obtain better signal intensity. The FAERS database consisted of seven data files: patient demographic information (DEMO), drug information (DRUG), adverse event information (REAC), patient outcome information (OUTC), report source information (RPSR), drug therapy date information (THER), and drug indication (INDI) [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. The data was retrieved using the keywords “pegvaliase/palynziq/pegvaliase-pqpz” for collecting patient demographics, drug information, AE information, patient outcomes and so on to further statistically analyze.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12181874_13023_2025_3864_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c5/12181874/e1f9249328ae/13023_2025_3864_Fig1_HTML.jpg" loading="lazy" id="d33e274" height="398" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>FDA FAERS Database Mining Workflow Diagram</p></figcaption></figure><p id="Par10">The System organ class (SOC), High Level Group Term (HLGT), High Level Term (HLT), Preferred term (PT), and Lowest Level Term (LLT) comprise the hierarchical structure of the MedDRA nomenclature [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. All valid pegvaliase-related AEs in our study were coded using preferred terms (PTs) and grouped into the System Organ Class (SOC) according to the Medical Dictionary for Regulatory Activities (MedDRA) version 26.1.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par11">The proportional disequilibrium method and Bayesian method are critical analytical tools utilized in the field of pharmacovigilance. The proportional disequilibrium method involves a comparison of the occurrence proportions of adverse events between a target drug and all other drugs. Both the proportional reported odds ratio (PRR) and the reported odds ratio (ROR) are included in this analysis [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. On the other hand, the Bayesian method incorporates two prominent algorithms: the Bayesian confidence propagation neural network (BCPNN) and the multiple Gamma Poisson reduction method (MGPS) [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. In order to gain more reliable results, this study adopted four distinct algorithms: ROR, PRR, BCPNN, and MGPS. Table <a href="#Tab1" class="usa-link">1</a> shows the four-cell table of the ratio imbalance method. The four algorithms were summarized in Table <a href="#Tab2" class="usa-link">2</a>, which were used to quantify the signal strength value representing the relevance between the interested drug and specific AE. If the criteria listed in Table <a href="#Tab2" class="usa-link">2</a> were met simultaneously, an AE would be considered highly associated with the treatment of the interested drug, with higher values indicating a more robust statistical correlation. Data regarding gender, age, reported year, reporter, geographical distribution, outcome of AEs weredisplayed using descriptive statistics and the count, data were expressed as frequency(%). Moreover, time-to-onset data that was defined as the period of time from the initiation of the use of pegvaliase to the onset of AEs were analyzed using the Weibull shape parameter (WSP) test. The incidence of AEs after the initiation of treatment depends on the drug mechanism of action and often varies over time. In contrast AEs that are not associated with drug treatment occur at aconstant rate. The WSP test can determine the varying ratio of incidence of AEs. All analyses were performed using Rsoftware version 4.3.1(The R Foundation for Statistical. Computing, Vienna. Austria).</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Four-cell table of proportional disequilibrium method</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Drugs</th>
<th align="left" colspan="1" rowspan="1">Target adverse reaction</th>
<th align="left" colspan="1" rowspan="1">Other adverse reactions</th>
<th align="left" colspan="1" rowspan="1">Total</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Target drug</td>
<td align="left" colspan="1" rowspan="1">a</td>
<td align="left" colspan="1" rowspan="1">b</td>
<td align="left" colspan="1" rowspan="1">a + b</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other drugs</td>
<td align="left" colspan="1" rowspan="1">c</td>
<td align="left" colspan="1" rowspan="1">d</td>
<td align="left" colspan="1" rowspan="1">c + d</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Total</td>
<td align="left" colspan="1" rowspan="1">a + c</td>
<td align="left" colspan="1" rowspan="1">b + d</td>
<td align="left" colspan="1" rowspan="1">n = a + b + c + d</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p16"><p>a: the number of reports containing both the suspect drug and the suspect adverse drug reaction; b: the number of reports containing the suspect adverse drug reaction with other medications (except the drug of interest); c: the number of reports containing the suspect drug with other adverse drug reactions (except the event of interest); d: the number of reports containing other medications and other adverse drug reactions; n: the number of all reports</p></div></div></section><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Four major algorithms used for signal detection</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Algorithms</th>
<th align="left" colspan="1" rowspan="1">Equation</th>
<th align="left" colspan="1" rowspan="1">Criteria</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="2" colspan="1">ROR</td>
<td align="left" colspan="1" rowspan="1">ROR = ad/b/c</td>
<td align="left" rowspan="2" colspan="1">lower limit of 95% CI &gt; 1, <em>N</em> ≥ 3</td>
</tr>
<tr><td align="left" colspan="1" rowspan="1">95%CI = e<sup>ln(ROR)±1.96(1/a+1/b+1/c+1/d)^0.5</sup>
</td></tr>
<tr>
<td align="left" rowspan="2" colspan="1">PRR</td>
<td align="left" colspan="1" rowspan="1">PRR = a(c + d)/c/(a + b)</td>
<td align="left" rowspan="2" colspan="1">PRR ≥ 2, χ<sup>2</sup> ≥ 4, <em>N</em> ≥ 3</td>
</tr>
<tr><td align="left" colspan="1" rowspan="1">χ<sup>2</sup>=[(ad-bc)^2](a + b + c + d)/[(a + b)(c + d)(a + c)(b + d)]</td></tr>
<tr>
<td align="left" rowspan="2" colspan="1">BCPNN</td>
<td align="left" colspan="1" rowspan="1">IC = log<sub>2</sub>a(a + b + c + d)(a + c)(a + b)</td>
<td align="left" rowspan="2" colspan="1">IC025 &gt; 0</td>
</tr>
<tr><td align="left" colspan="1" rowspan="1">95%CI = E(IC) ± 2 V(IC)^0.5</td></tr>
<tr>
<td align="left" rowspan="2" colspan="1">EBGM</td>
<td align="left" colspan="1" rowspan="1">EBGM = a(a + b + c + d)/(a + c)/(a + b)</td>
<td align="left" rowspan="2" colspan="1">EBGM05 &gt; 2</td>
</tr>
<tr><td align="left" colspan="1" rowspan="1">95%CI = e<sup>ln(EBGM)±1.96(1/a+1/b+1/c+1/d)^0.5</sup>
</td></tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p19"><p>Equation: a, number of reports containing both the target drug and target adverse drug reaction; b, number of reports containing other adverse drug reaction of the target drug; c, number of reports containing the target adverse drug reaction of other drugs; d, number of reports containing other drugs and other adverse drug reactions. 95%CI, 95% confidence interval; N, the number of reports; χ<sup>2</sup>, chi-squared; IC, information component; IC025, the lower limit of 95% CI of the IC; E(IC), the IC expectations; V(IC), the variance of IC; EBGM, empirical Bayesian geometric mean; EBGM05, the lower limit of 95% CI of EBGM</p></div></div></section></section></section><section id="Sec5"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec6"><h3 class="pmc_sec_title">General characteristics</h3>
<p id="Par14">Following a sequence of data processing steps, 5,076 adverse event reports of pegvaliase as the PS were acquired from 2018 Q3 to 2023 Q2. The detailed data processing procedure is shown in Fig. <a href="#Fig1" class="usa-link">1</a>.The characteristics of the AE reports that were turned in for pegvaliase are shown in Table <a href="#Tab3" class="usa-link">3</a>. The proportion of females (41.2%) was higher than that of males (27.4%), with 31.4% of unknown sex cases. Patients between the ages of 18 and 45 accounted for the highest proportions of reports, comprising 34.12%. Furthermore, with 58.2% (<em>n</em> = 2953) of the age group that was not identified, it also represented a sizeable amount. Following the medicine’s debut in 2018, the number of reported AEs had progressively increased, peaked in 2020 (23.1%), and then gradually dropped thereafter. Most of the reports were submitted by consumers (83.0%), followed by physicians (3.9%), pharmacists (1.0%), other health professionals (0.7%), and not specified people (11.3%). America reported the highest percentage (98.2%), followed by Germany (1.5%) and Italy (0.2%). The most commonly reported severe outcome was other serious medical event with 571 cases (11.1%), followed by hospitalization with 151 cases (2.9%), life-threatening situations with 40 cases (0.8%), death with 6 cases (0.1%), and disability with 2 cases (0.0%). From Table <a href="#Tab3" class="usa-link">3</a> of the database, we extracted the times at which adverse events pertaining to pegvaliase occurred. However, 2759 (54.4%) of the cases did not report the onset time of AEs. The median start time was 15 days with an interquartile range (IQR) of 1 to 2,372 days. The majority of AEs happened in the initial month (<em>n</em> = 1591, 31.3%), followed by 31–60 days (<em>n</em> = 322, 6.3%), 61–90 days(2.0%). There were also cases reported between more than 360 days (<em>n</em> = 94, 1.9%), 91–120 days (<em>n</em> = 76, 1.5%), 181–360 days (<em>n</em> = 74, 1.5%), 151–180 days (<em>n</em> = 34, 0.7%), and 121–150 days (<em>n</em> = 23, 0.5%) following the start of pegvaliase. It was noteworthy that our findings suggested that adverse events were most likely to occur in the early stages.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Clinical characteristics of reports with Pegvaliase from the FAERS database (2018 Q3 to 2023 Q2)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Characteristics</th>
<th align="left" colspan="1" rowspan="1">Case Number, <em>n</em>
</th>
<th align="left" colspan="1" rowspan="1">Case Proportion, %</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>Gender</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="center" colspan="1" rowspan="1">2090</td>
<td align="center" colspan="1" rowspan="1">41.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male</td>
<td align="center" colspan="1" rowspan="1">1392</td>
<td align="center" colspan="1" rowspan="1">27.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not Specified</td>
<td align="center" colspan="1" rowspan="1">1594</td>
<td align="center" colspan="1" rowspan="1">31.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>Age(Years)</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 18</td>
<td align="center" colspan="1" rowspan="1">84</td>
<td align="center" colspan="1" rowspan="1">1.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 18, &lt;45</td>
<td align="center" colspan="1" rowspan="1">2032</td>
<td align="center" colspan="1" rowspan="1">40.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 45, &lt;65</td>
<td align="center" colspan="1" rowspan="1">7</td>
<td align="center" colspan="1" rowspan="1">0.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not Specified</td>
<td align="center" colspan="1" rowspan="1">2953</td>
<td align="center" colspan="1" rowspan="1">58.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>Reported year</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2023</td>
<td align="center" colspan="1" rowspan="1">764</td>
<td align="center" colspan="1" rowspan="1">15.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2022</td>
<td align="center" colspan="1" rowspan="1">887</td>
<td align="center" colspan="1" rowspan="1">17.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2021</td>
<td align="center" colspan="1" rowspan="1">1136</td>
<td align="center" colspan="1" rowspan="1">22.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2020</td>
<td align="center" colspan="1" rowspan="1">1173</td>
<td align="center" colspan="1" rowspan="1">23.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2019</td>
<td align="center" colspan="1" rowspan="1">971</td>
<td align="center" colspan="1" rowspan="1">19.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2018</td>
<td align="center" colspan="1" rowspan="1">145</td>
<td align="center" colspan="1" rowspan="1">2.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>Reporters</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Consumer</td>
<td align="center" colspan="1" rowspan="1">4214</td>
<td align="center" colspan="1" rowspan="1">83.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not Specified</td>
<td align="center" colspan="1" rowspan="1">576</td>
<td align="center" colspan="1" rowspan="1">11.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Physician</td>
<td align="center" colspan="1" rowspan="1">197</td>
<td align="center" colspan="1" rowspan="1">3.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other health-professional</td>
<td align="center" colspan="1" rowspan="1">38</td>
<td align="center" colspan="1" rowspan="1">0.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pharmacist</td>
<td align="center" colspan="1" rowspan="1">51</td>
<td align="center" colspan="1" rowspan="1">1.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>Report countries</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Argentina</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">0.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not Specified</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">0.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Germany</td>
<td align="center" colspan="1" rowspan="1">75</td>
<td align="center" colspan="1" rowspan="1">1.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">United Kingdom</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">0.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Italy</td>
<td align="center" colspan="1" rowspan="1">9</td>
<td align="center" colspan="1" rowspan="1">0.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Japan</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">0.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kuwait</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">0.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Russia</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">0.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">The United States</td>
<td align="center" colspan="1" rowspan="1">4984</td>
<td align="center" colspan="1" rowspan="1">98.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>Outcomes</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Death</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="center" colspan="1" rowspan="1">0.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Disability</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">0.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hospitalization-Initial or Prolonged</td>
<td align="center" colspan="1" rowspan="1">151</td>
<td align="center" colspan="1" rowspan="1">2.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Life-Threatening</td>
<td align="center" colspan="1" rowspan="1">40</td>
<td align="center" colspan="1" rowspan="1">0.8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other Serious (Important Medical Event)</td>
<td align="center" colspan="1" rowspan="1">571</td>
<td align="center" colspan="1" rowspan="1">11.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not Specified</td>
<td align="center" colspan="1" rowspan="1">4364</td>
<td align="center" colspan="1" rowspan="1">85.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Time to onset</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">0–30 d</td>
<td align="center" colspan="1" rowspan="1">1591</td>
<td align="center" colspan="1" rowspan="1">31.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">121–150 d</td>
<td align="center" colspan="1" rowspan="1">23</td>
<td align="center" colspan="1" rowspan="1">0.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">151–180 d</td>
<td align="center" colspan="1" rowspan="1">34</td>
<td align="center" colspan="1" rowspan="1">0.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">181–360 d</td>
<td align="center" colspan="1" rowspan="1">74</td>
<td align="center" colspan="1" rowspan="1">1.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">31–60 d</td>
<td align="center" colspan="1" rowspan="1">322</td>
<td align="center" colspan="1" rowspan="1">6.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">61–90 d</td>
<td align="center" colspan="1" rowspan="1">103</td>
<td align="center" colspan="1" rowspan="1">2.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">91–120 d</td>
<td align="center" colspan="1" rowspan="1">76</td>
<td align="center" colspan="1" rowspan="1">1.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt; 360 d</td>
<td align="center" colspan="1" rowspan="1">94</td>
<td align="center" colspan="1" rowspan="1">1.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not Specified or missing</td>
<td align="center" colspan="1" rowspan="1">2759</td>
<td align="center" colspan="1" rowspan="1">54.4</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec7"><h3 class="pmc_sec_title">Signal detection</h3>
<p id="Par16">Signal strength and pegvaliase reports at the System Organ Class (SOC) level, ranked by the frequency of adverse events, were shown in Table <a href="#Tab4" class="usa-link">4</a>. According to statistics, we discovered that 27 SOCs were all targeted by pegvaliase-induced AEs. General disorders and administration site conditions (32.11%), musculoskeletal and connective tissue disorders (11.93%), skin and subcutaneous tissue disorders (11.18%), nervous system disorders (7.97%), gastrointestinal disorders (7.49%) were the five most common systems. The study used the four algorithms ROR, PRR, BPCNN and EBGM to examine the adverse reactions of the drug and to assess whether it meet pre-defined screening criteria. The four algorithms identified a total of 5,076 AEs. Figure <a href="#Fig2" class="usa-link">2</a> shows that a total of 83 PTs, which adhere to all four algorithms, were detected among these PTs. Ranked by the frequency (Fig. <a href="#Fig3" class="usa-link">3</a> and Supplementary Table <a href="#MOESM1" class="usa-link">1</a>), the top 5 PTs include arthralgia (ROR 12.11, 95%CI 11.3-12.94), injection site reaction (ROR 62.83, 95% CI 57.71–68.4), injection site erythema (ROR 35.37, 95%CI 32.35–38.68); rash (ROR 3.91, 95%CI 3.51–4.35), and injection site swelling (ROR 30.7, 95%CI 27.5-34.26). Ranked by the signal intensities (Fig. <a href="#Fig4" class="usa-link">4</a> and Supplementary Table <a href="#MOESM1" class="usa-link">2</a>), the top 5 PTs include amino acid level decreased (ROR 4800.89, 95%CI 3518.63-6550.43), amino acid level abnormal (ROR 1824.26, 95%CI 988.6-3366.3), amino acid level increased (ROR 571.87, 95%CI 449.86-726.96), fibrosarcoma metastatic (ROR 478.13, 95%CI 53.44-4278.26), and phenylketonuria (ROR 382.57, 95%CI 110.74-1321.66), which may be related to diseases of the patients.</p>
<section class="tw xbox font-sm" id="Tab4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>Number of AEs of Pegvaliase at the system organ class (SOC) level in FAERS database</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">SOC</th>
<th align="left" colspan="1" rowspan="1">
<em>N</em>
</th>
<th align="left" colspan="1" rowspan="1">proportion(%)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">General Disorders And Administration Site Conditions</td>
<td align="center" colspan="1" rowspan="1">3959</td>
<td align="center" colspan="1" rowspan="1">32.11</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gastrointestinal Disorders</td>
<td align="center" colspan="1" rowspan="1">923</td>
<td align="center" colspan="1" rowspan="1">7.49</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nervous System Disorders</td>
<td align="center" colspan="1" rowspan="1">983</td>
<td align="center" colspan="1" rowspan="1">7.97</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Skin And Subcutaneous Tissue Disorders</td>
<td align="center" colspan="1" rowspan="1">1378</td>
<td align="center" colspan="1" rowspan="1">11.18</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Musculoskeletal And Connective Tissue Disorders</td>
<td align="center" colspan="1" rowspan="1">1471</td>
<td align="center" colspan="1" rowspan="1">11.93</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychiatric Disorders</td>
<td align="center" colspan="1" rowspan="1">350</td>
<td align="center" colspan="1" rowspan="1">2.84</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Blood And Lymphatic System Disorders</td>
<td align="center" colspan="1" rowspan="1">43</td>
<td align="center" colspan="1" rowspan="1">0.35</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Respiratory, Thoracic And Mediastinal Disorders</td>
<td align="center" colspan="1" rowspan="1">720</td>
<td align="center" colspan="1" rowspan="1">5.84</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Infections And Infestations</td>
<td align="center" colspan="1" rowspan="1">435</td>
<td align="center" colspan="1" rowspan="1">3.53</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Eye Disorders</td>
<td align="center" colspan="1" rowspan="1">97</td>
<td align="center" colspan="1" rowspan="1">0.79</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Metabolism And Nutrition Disorders</td>
<td align="center" colspan="1" rowspan="1">108</td>
<td align="center" colspan="1" rowspan="1">0.88</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Investigations</td>
<td align="center" colspan="1" rowspan="1">511</td>
<td align="center" colspan="1" rowspan="1">4.14</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Immune System Disorders</td>
<td align="center" colspan="1" rowspan="1">468</td>
<td align="center" colspan="1" rowspan="1">3.8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Vascular Disorders</td>
<td align="center" colspan="1" rowspan="1">142</td>
<td align="center" colspan="1" rowspan="1">1.15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Injury, Poisoning And Procedural Complications</td>
<td align="center" colspan="1" rowspan="1">376</td>
<td align="center" colspan="1" rowspan="1">3.05</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cardiac Disorders</td>
<td align="center" colspan="1" rowspan="1">84</td>
<td align="center" colspan="1" rowspan="1">0.68</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pregnancy, Puerperium And Perinatal Conditions</td>
<td align="center" colspan="1" rowspan="1">39</td>
<td align="center" colspan="1" rowspan="1">0.32</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Reproductive System And Breast Disorders</td>
<td align="center" colspan="1" rowspan="1">30</td>
<td align="center" colspan="1" rowspan="1">0.24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Social Circumstances</td>
<td align="center" colspan="1" rowspan="1">12</td>
<td align="center" colspan="1" rowspan="1">0.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Product Issues</td>
<td align="center" colspan="1" rowspan="1">24</td>
<td align="center" colspan="1" rowspan="1">0.19</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Renal And Urinary Disorders</td>
<td align="center" colspan="1" rowspan="1">44</td>
<td align="center" colspan="1" rowspan="1">0.36</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hepatobiliary Disorders</td>
<td align="center" colspan="1" rowspan="1">16</td>
<td align="center" colspan="1" rowspan="1">0.13</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Surgical And Medical Procedures</td>
<td align="center" colspan="1" rowspan="1">30</td>
<td align="center" colspan="1" rowspan="1">0.24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Congenital, Familial And Genetic Disorders</td>
<td align="center" colspan="1" rowspan="1">9</td>
<td align="center" colspan="1" rowspan="1">0.07</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ear And Labyrinth Disorders</td>
<td align="center" colspan="1" rowspan="1">40</td>
<td align="center" colspan="1" rowspan="1">0.32</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Endocrine Disorders</td>
<td align="center" colspan="1" rowspan="1">10</td>
<td align="center" colspan="1" rowspan="1">0.08</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps)</td>
<td align="center" colspan="1" rowspan="1">27</td>
<td align="center" colspan="1" rowspan="1">0.22</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12181874_13023_2025_3864_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c5/12181874/91f073ba32cb/13023_2025_3864_Fig2_HTML.jpg" loading="lazy" id="d33e1107" height="519" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Signals identified by the four algorithms (ROR, PRR, BPCNN, and EBGM)</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12181874_13023_2025_3864_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c5/12181874/bfa616ff946f/13023_2025_3864_Fig3_HTML.jpg" loading="lazy" id="d33e1117" height="294" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The top 20 AEs of Pegvaliase at preferred terms (PTs) level ranked by Case Numbers in FDA Adverse Event Reporting System (FAERS)</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12181874_13023_2025_3864_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c5/12181874/605c9486ec2b/13023_2025_3864_Fig4_HTML.jpg" loading="lazy" id="d33e1127" height="285" width="669" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The top 20 AEs of Pegvaliase at preferred terms (PTs) level ranked by signal strength in FDA Adverse Event Reporting System (FAERS)</p></figcaption></figure></section><section id="Sec8"><h3 class="pmc_sec_title">Subgroup analyses</h3>
<p id="Par21">We use subgroup analysis for additional research to thoroughly examine the data outcomes. Referring to Supplementary Fig. <a href="#MOESM1" class="usa-link">1</a>, the male’s top 5 PTs according to signal intensities were arthralgia (ROR 15.96, 95%CI 14.13–18.03), injection site reaction (ROR 80.48, 95%CI 68.16–95.03), injection site erythema (ROR 61.51, 95%CI 51.98–72.78), injection site swelling (ROR 44.08, 95%CI 36.06–53.87), and rash (ROR 3.97, 95%CI 3.22–4.9). The female’s top 5 PTs according to signal intensities were arthralgia (ROR 9.9, 95%CI 8.92–10.99), injection site erythema (ROR 30.18, 95%CI 26.53–34.34); injection site reaction (ROR 52.73, 95%CI 46.27–60.1), rash (ROR 4.08, 95%CI 3.49–4.77), and headache (ROR 2.57, 95%CI 2.18–3.01). We could find that the adverse reactions to pegvaliase were mostly the same in people of different sexes.</p>
<p id="Par22">We also examined the ranking of AEs and age based on signal intensity (Supplementary Fig. <a href="#MOESM1" class="usa-link">2</a>). For those under the age of 18, the top 5 PTs were as follows: arthralgia (ROR 34.45, 95%CI 22.64–52.42); urticaria (ROR 11.15, 95%CI 6.39–19.47); injection site reaction (ROR 62.62, 95%CI 34.17-114.78); injection site swelling (ROR 44, 95%CI 24.03–80.57); vomiting (ROR2.58, 95%CI 1.33–5.01). Regarding the ≥ 18, &lt;65 age range, the top 5 PTs were as follows: arthralgia (ROR 9.98, 95%CI 9.01–11.05); injection site erythema (ROR 15.81, 95%CI 13.88–18.02); injection site reaction (ROR 30.44, 95%CI 26.71–34.7); headache (ROR 2.2, 95%CI 1.88–2.58); injection site swelling (ROR 17.59, 95%CI 14.99–20.63). Regarding the age bracket of ≥ 65, the top 5 PTs were as follows: peripheral swelling (ROR 38.98, 95%CI 8.96-169.55); injection site reaction (ROR 136.24, 95%CI 18.13-1023.96); abdominal distension (ROR 36.07, 95%CI 4.8-271.03); headache (ROR 7.82, 95%CI 1.04–58.77); fatigue (ROR 4.67, 95%CI 0.62–35.13). We could find that the adverse reactions to pegvaliase were mostly the same in people of different ages, occurred mainly between the ages of 18–65 years.</p>
<p id="Par23">Additionally, we explored the relationship between reporters and AEs ranked by the signal intensities (Supplementary Fig. <a href="#MOESM1" class="usa-link">3</a>). The health professional’s top 5 PTs according to signal intensities were arthralgia (ROR 10.73, 95%CI 8.06–14.28), anaphylactic reaction (ROR 28.08, 95%CI 19.5-40.44), rash (ROR 2.9, 95%CI 1.88–4.47), nausea (ROR 2.28, 95%CI 1.48–3.51), and headache (ROR 3.36, 95%CI 2.18–5.18). The consumer’s top 5 PTs according to signal intensities were arthralgia (ROR 11.53, 95%CI 10.72–12.4), injection site reaction (ROR 70.08, 95%CI 63.97–76.78), injection site erythema (ROR 31.79, 95%CI 28.86–35.03), injection site swelling (ROR 29.09, 95%CI 25.77–32.83), and rash (ROR 3.93, 95%CI 3.49–4.44). We could find that the adverse reactions to pegvaliase were mostly the same in people of different reporters.</p>
<p id="Par24">We also explored the impact of different genders, ages and reporters on the time to onset time (Fig. <a href="#Fig5" class="usa-link">5</a>). Based on the analysis provided, the median onset time of pegvaliase was 15.00 days (with a range of 1.00-2372.00 days). In our analysis of subgroups, it was found that females had a median time to events of 15.00 days (IQR 1.00-1880.00), while males had a median time of 14.00 days (IQR 1.00-2372.00). The median onset time of pegvaliase for individuals under 18 years old, ≧18 and &lt; 65, and ≧ 65 was 16.00 (IQR 8.00-2372.00), 15.00 (IQR 1.00-1880.00), and 13.50 (IQR 12.00–15.00) respectively. The results showed that the customers had a median time to event of 15.00 days (IQR 1.00-1428.00), whereas the health professionals had a median time to incident of 15.00 days (IQR 1.00-2372.00).</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12181874_13023_2025_3864_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c5/12181874/dba3bb97f360/13023_2025_3864_Fig5_HTML.jpg" loading="lazy" id="d33e1159" height="635" width="669" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Subgroup analyses of Time to onset</p></figcaption></figure></section></section><section id="Sec9"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par26">Pegvaliase is a new enzyme substitution therapy that decreases blood Phe without the need of PAH or its BH4 cofactor [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. The standard therapy of PKU includes a Phe-restricted diet plus medical nutrition therapy (MNT), with or without sapropterin dihydrochloride, to reduce blood Phe levels. Compared with standard therapy, pegvaliase induces a substantial, progressive, and sustained decrease in blood Phe levels - to a much greater extent than sapropterin combined with MNT or MNT alone - which is expected to improve long-term outcomes in patients with PKU [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. A series of studies have confirmed that pegvaliase has more significant efficacy of pegvaliase in the treatment of PKU. Nevertheless, at the same time, the management of its AEs still cannot be ignored. Previous research on AEs to Pegvaliase primarily relied heavily on clinical studies and case reports. Nevertheless, strict trial designs and stringent inclusion criteria might have led to the underreporting of rare AEs, resulting in incomplete drug safety information. Our study systematically evaluated the adverse reactions related to pegvaliase by in-depth analysis of the FAERS database from 2018 Q3 to 2023 Q2. In this process, this study not only confirmed some existing safety information, but also revealed new potential risks. This provides more comprehensive and accurate data support for medical practice and medication decisions.</p>
<p id="Par27">The results of our study show that the number of patients with adverse events is slightly more in women than in men. This could mean that women were more likely to report these side effects or that they were more vulnerable to pegvaliase’s negative effects. The most common age group in these reports is 18 to 45 years old, most likely because this is the age group that uses the drug the most. Pegvaliase is authorized as an enzyme-substitution therapy for adults (US) or patients aged ≥ 16 years (Europe) with PKU and uncontrolled blood Phe concentrations &gt; 600µmol/L on current management. The safety and effectiveness of pegvaliase in populations under the age of 16 are currently the subject of very limited information. In one study, a 12-year-old girl was closely monitored while using Pegvaliase, and the results were excellent and her safety profile was good [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. With the advancement of medical research, the drug is expected to be used in patients under the age of 16. To validate these results, nevertheless, greater sample sizes and sound methodology are needed. Reports of adverse reactions increased each year during the first three years of the drug’s availability, which we believe may be related to a lack of awareness of the drug among healthcare professionals and patients, or perhaps an increase in the use of the drug. With the introduction of guidelines and prevention of adverse effects by healthcare professionals and patients, the number of reported AEs was decreasing year by year. Furthermore, we discovered that 83% of the reporters were not medical professionals like doctors, pharmacists, or nurses, but rather consumers. Because the FAERS is a self-reporting system, not everyone is willing to record AEs, which could result in variations in the reporting population’s characteristics. Almost all reports are from the United States, which may be due to the fact that pegvaliase was initially marketed in the United States or due to limitations in the FAERS database. Notably, a total of 199 cases of serious outcomes, such as death, disability requiring hospitalization or life-threatening conditions, were recorded in the outcome section. But unfortunately, the FAERS database lacked sufficient information to assess the possible link between pegvaliase use and serious outcomes. The timing of adverse reactions was mainly in the first 6 months after dosing, which is consistent with the results of clinical trials. It is worth noting that roughly half of the data does not include precise timeframes for adverse events to occur, which restricts our comprehension of how adverse events occur at various drug periods. Accurate medication time data is necessary for future study, which examines how the medicine reacts differently at various medication times.</p>
<p id="Par28">Our study showed that common PTs of pegvaliase in terms of frequency include arthralgia, injection site reaction, injection site erythema, rash, injection site swelling, et al., which are were generally consistent with the drug inserts and clinical trial results [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>, <a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>, <a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. Final results from the long-term Phase 3 clinical trial program show that the most commonly reported AEs of pegvaliase were arthralgia, injection-site reaction (ISR), injection-site erythema, and headache, which occurred most frequently during the first 6 months of therapy and most were mild or moderate in severity. Furthermore, of the 261 participants treated with pegvaliase, a total of 101 patients discontinued the trial, including 69.0% of patients (54 in the PRISM-1 study, 46 in the PRISM-2 study, and 1 in the 165–304 study) due to adverse events occurring during the first six months of treatment [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. Pegvaliase is a bacterially derived protein, patients produce anti-drug antibodies to pegvaliase and immunologic adverse events (AEs) are expected [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. A common worry with biologic therapies is immunogenicity, especially when it comes to nonhuman enzymes. HAEs were identified using a modified hypersensitivity SMQ, which included the additional preferred term AEs of arthralgia, arthritis, eye inflammation, eye irritation, eye pain, joint stiffness, joint swelling, pyrexia, blurred vision and polyarthritis, and the broad algorithmic anaphylactic reaction SMQ. The results of studies demonstrate that development of HAEs was temporally associated with immune response rather than pegvaliase plasma levels. Patients without anaphylaxis or SAEs and those with fewer HAEs throughout the PRISM-1 induction and titration phases generally had lower ADA titers and greater pegvaliase Ctrough. Patients with higher pegvaliase trough plasma concentrations typically had lower ADA titers and a more favorable tolerability profile. When administered doses of pegvaliase were low and both circulating immune complex concentrations and HAEs were peaking during induction/titration. Over time, the frequency of HAEs decreased as circulating immune complex concentrations decreased [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. Therefore, a protocol for induction, titration, and maintenance (I/T/M) dosage is followed when administering pegvaliase in order to minimise the incidence of serious adverse events [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Beginning with low-dose injections for four weeks (an induction period of 2.5 mg/week), the dosage is progressively increased to a maintenance dose of up to 60 mg daily, contingent upon patient tolerance and pharmacological efficacy. The duration of time needed to achieve efficacy on pegvaliase and the dosage needed vary due to individual immune response [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. The maximum dose for pegvaliase prescribed by the FDA at this time is 60 mg per day. According to studies, increasing the dosage of pegvaliase to 80 mg per day may be effective for patients who don’t respond well at lower doses, and pegvaliase dosing must be personalized to achieve therapeutic goals [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>].</p>
<p id="Par29">From the results of the study, we can find that Amino Acid Level Decreased, Amino Acid Level Abnormal, and Amino Acid Level Increased ranked high on the ROR, and that there is a mechanistic link between fluctuations in amino acid levels (especially Phe) and the enzymatic activity of pegvaliase. As a phenylalanine metabolizing enzyme, pegvaliase directly regulates the concentration of Phe, and the transient amino acid changes may reflect efficacy rather than toxicity, as tight control of Phe remains the primary therapeutic goal in PKU. We believe that the clinical significance depends on the magnitude and duration of the deviation: hypophenylalaninemia (blood Phe &lt; 30 µmol/L) is likely to result in proteolytic metabolism; persistent elevation of blood Phe above 360 µmol/L may result in neurocognitive deficits. the lack of quantitative data to assess severity in FAERS cases is a shortcoming. Additionally, signal strength analysis expose several potential PTs not documented in Pegvaliase’s instructions, including Fibrosarcoma Metastatic, Phenylketonuria, Fascia Release, and Gallbladder Hyperfunction. A search was conducted using databases such as PubMed with the search terms Pegvaliase, Fibrosarcoma Metastatic, phenylketonuria, Fascia Release, and Gallbladder Hyperfunction. No case reports were found in the search results. These PTs might, in the context of clinical practice, be false positive data or infrequent, undetected ADR signals. Therefore, it is important for clinicians to pay attention to and validate these potential adverse drug reactions (ADRs) during the use of Pegvaliase, even though they are not listed in the drug manual [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. To improve drug tolerability, especially during the initial treatment phase when HAEs are most frequent, specific measures can be implemented. One way to minimize the risks associated with initial treatment is by following I/T/M dosing regimens [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Additionally, until patients and observers are able to confidently manage dosing and recognize HAE symptoms, initial pegvaliase doses should be administered under the supervision of a healthcare practitioner. All patients taking pegvaliase should have access to autoinjectable epinephrine in order to treat any potential acute systemic hypersensitivity reaction (ASHR), and they should also receive education on how to identify ASHR symptoms and manage them [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>, <a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. Patients who experience episodes of arthralgia can use drugs like acetaminophen to control their symptoms. It is advised that patients switch up their injection sites to avoid injection site reactions. Topical H1-antihistamines, topical steroids, or cold compresses can all be used to treat these symptoms [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>, <a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Another therapeutic strategy for severe and recurring HAEs could be 13-step desensitization, which would allow the medication to continue to be successful [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. Dose reduction is often more beneficial than stopping treatment after a HAE because it preserves the “desensitizing” impact of ongoing antigen exposure. Based on the severity of the occurrence, a temporary dose reduction might be required. Reversing the dosage schedule by one or two steps may be necessary for this.</p></section><section id="Sec10"><h2 class="pmc_sec_title">Limitations</h2>
<p id="Par30">This study provides valuable insights into the safety profile of pegvaliase through the use of the FAERS database, offering a real-world perspective on post-market AEs.Nonetheless, a number of restrictions must be noted. First, the FAERS database relies on spontaneous reporting, which is prone to incomplete data, underreporting, and reporting bias. This may cause some adverse events to be overreported while others are underreported, especially in regions or countries with weaker reporting systems. Furthermore, the absence of long-term follow-up data in the FAERS database restricts our capacity to evaluate the persistence and long-term effects of AEs linked to pegvaliase. Long-term medication safety is a crucial factor in inherited diseases, thus this is especially crucial. Lastly, the FAERS database cannot establish a causal relationship between medications and adverse events, it can only identify associational signals. Confounding factors such as patient individual differences, comorbidities, and medication history may influence the occurrence of adverse events. Therefore, results interpretation must be more cautious to avoid over inferring causality.</p></section><section id="Sec11"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par31">This study retrospectively analyzed the AEs data of pegvaliase in the FAERS database, and further analyzed the data using a variety of algorithms. The data were also analyzed in subgroups at different levels such as gender, age, reporters and time to onset. This study obtained more authentic and complete drug safety information, which can provide reference for clinical drug use and promote rational clinical drug use. In this process, this study not only confirmed some existing safety information, but also revealed new potential risks. Pegvaliase is one of the few medications available for the treatment of PKU, so it is critical to educate patients and their caregivers about pegvaliase treatment, dosing, and the risks of AEs, especially during the first 6 months of treatment.</p></section><section id="Sec12"><h2 class="pmc_sec_title">Electronic supplementary material</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12181874/bin/13023_2025_3864_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (699.4KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We acknowledge the support received from Quzhou technology projects, China [2023K141].</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>LuYao Xu conceived, designed the study and wrote the original draft. KaiLi Mao and SongYang Zhong performed the research and analyzed the data. HuaYu Sun and HongLiang Zheng reviewed and edited the article. ZhenLing Fu participated in the interpretation of the data and revised and approved the final article as submitted.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was supported by Quzhou technology projects, China [2023K141].</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>Data are available on the FAERS database.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar3"><h3 class="pmc_sec_title">Ethics approval</h3>
<p id="Par32">Not applicable.</p></section><section id="FPar4"><h3 class="pmc_sec_title">Consent to participate</h3>
<p id="Par33">Not applicable.</p></section><section id="FPar1"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par34">Not applicable.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Conflict of interest</h3>
<p id="Par35">The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, Chiesa AE, Christodoulou J, Đorđević M, Desviat LR, Eliyahu A, Evers RAF, Fajkusova L, Feillet F, Bonfim-Freitas PE, Giżewska M, Gundorova P, Karall D, Kneller K, Kutsev SI, Leuzzi V, Levy HL, Lichter-Konecki U, Muntau AC, Namour F, Oltarzewski M, Paras A, Perez B, Polak E, Polyakov AV, Porta F, Rohrbach M, Scholl-Bürgi S, Spécola N, Stojiljković M, Shen N, Santana-da LC, Silva A, Skouma F, van Spronsen V, Stoppioni B, Thöny FK, Trefz J, Vockley Y, Yu J, Zschocke GF, Hoffmann SF, Garbade N, Blau. The Genetic Landscape and Epidemiology of Phenylketonuria, The American Journal of Human Genetics 107(2) (2020) 234–250.</cite> [<a href="https://doi.org/10.1016/j.ajhg.2020.06.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7413859/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32668217/" class="usa-link">PubMed</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Muntau AC, Adams DJ, Bélanger-Quintana A, Bushueva TV, Cerone R, Chien Y-H, Chiesa A, Coşkun T, de las Heras J, Feillet F, Katz R, Lagler F, Piazzon F, Rohr F, van Spronsen FJ, Vargas P, Wilcox G, Bhattacharya K. International best practice for the evaluation of responsiveness to Sapropterin dihydrochloride in patients with phenylketonuria. Mol Genet Metab. 2019;127(1):1–11.
</cite> [<a href="https://doi.org/10.1016/j.ymgme.2019.04.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31103398/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Muntau%20AC,%20Adams%20DJ,%20B%C3%A9langer-Quintana%20A,%20Bushueva%20TV,%20Cerone%20R,%20Chien%20Y-H,%20Chiesa%20A,%20Co%C5%9Fkun%20T,%20de%20las%20Heras%20J,%20Feillet%20F,%20Katz%20R,%20Lagler%20F,%20Piazzon%20F,%20Rohr%20F,%20van%20Spronsen%20FJ,%20Vargas%20P,%20Wilcox%20G,%20Bhattacharya%20K.%20International%20best%20practice%20for%20the%20evaluation%20of%20responsiveness%20to%20Sapropterin%20dihydrochloride%20in%20patients%20with%20phenylketonuria.%20Mol%20Genet%20Metab.%202019;127(1):1%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>van Spronsen FJ, van Wegberg AMJ, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, Huijbregts SC, Kearney S, Leuzzi V, Maillot F, Muntau AC, Trefz FK, van Rijn M, Walter JH, MacDonald A. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–56.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(16)30320-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28082082/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?van%20Spronsen%20FJ,%20van%20Wegberg%20AMJ,%20Ahring%20K,%20B%C3%A9langer-Quintana%20A,%20Blau%20N,%20Bosch%20AM,%20Burlina%20A,%20Campistol%20J,%20Feillet%20F,%20Gi%C5%BCewska%20M,%20Huijbregts%20SC,%20Kearney%20S,%20Leuzzi%20V,%20Maillot%20F,%20Muntau%20AC,%20Trefz%20FK,%20van%20Rijn%20M,%20Walter%20JH,%20MacDonald%20A.%20Key%20European%20guidelines%20for%20the%20diagnosis%20and%20management%20of%20patients%20with%20phenylketonuria.%20Lancet%20Diabetes%20Endocrinol.%202017;5(9):743%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochemist Reviews. 2008;29(1):31–41.</cite> [<a href="/articles/PMC2423317/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18566668/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Williams%20RA,%20Mamotte%20CD,%20Burnett%20JR.%20Phenylketonuria:%20an%20inborn%20error%20of%20phenylalanine%20metabolism.%20Clin%20Biochemist%20Reviews.%202008;29(1):31%E2%80%9341." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>ten Hoedt AE, de Sonneville LMJ, Francois B, ter Horst NM, Janssen MCH, Rubio-Gozalbo ME, Wijburg FA, Hollak CEM, Bosch AM. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double‐blind, placebo‐controlled, crossover trial. J Inherit Metab Dis. 2011;34(1):165–71.
</cite> [<a href="https://doi.org/10.1007/s10545-010-9253-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3026661/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21153445/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?ten%20Hoedt%20AE,%20de%20Sonneville%20LMJ,%20Francois%20B,%20ter%20Horst%20NM,%20Janssen%20MCH,%20Rubio-Gozalbo%20ME,%20Wijburg%20FA,%20Hollak%20CEM,%20Bosch%20AM.%20High%20phenylalanine%20levels%20directly%20affect%20mood%20and%20sustained%20attention%20in%20adults%20with%20phenylketonuria:%20a%20randomised,%20double%E2%80%90blind,%20placebo%E2%80%90controlled,%20crossover%20trial.%20J%20Inherit%20Metab%20Dis.%202011;34(1):165%E2%80%9371." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Blau N, van Spronsen FJ, Levy HL. Phenylketonuria Lancet. 2010;376(9750):1417–27.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(10)60961-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20971365/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Blau%20N,%20van%20Spronsen%20FJ,%20Levy%20HL.%20Phenylketonuria%20Lancet.%202010;376(9750):1417%E2%80%9327." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Sci. 2014;16(2):188–200.</cite> [<a href="https://doi.org/10.1038/gim.2013.157" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24385074/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vockley%20J,%20Andersson%20HC,%20Antshel%20KM,%20Braverman%20NE,%20Burton%20BK,%20Frazier%20DM,%20Mitchell%20J,%20Smith%20WE,%20Thompson%20BH,%20Berry%20SA.%20Phenylalanine%20hydroxylase%20deficiency:%20diagnosis%20and%20management%20guideline.%20Genet%20Sci.%202014;16(2):188%E2%80%93200." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Brumm VL, Bilder D, Waisbren SE. Psychiatric symptoms and disorders in phenylketonuria☆. Mol Genet Metab. 2010;99:S59–63.
</cite> [<a href="https://doi.org/10.1016/j.ymgme.2009.10.182" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20123472/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brumm%20VL,%20Bilder%20D,%20Waisbren%20SE.%20Psychiatric%20symptoms%20and%20disorders%20in%20phenylketonuria%E2%98%86.%20Mol%20Genet%20Metab.%202010;99:S59%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Sumaily KM, Mujamammi AH. Phenylketonuria: A new look at an old topic, advances in laboratory diagnosis, and therapeutic strategies. Int J Health Sci. 2017;11(5):63–70.</cite> [<a href="/articles/PMC5669513/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29114196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sumaily%20KM,%20Mujamammi%20AH.%20Phenylketonuria:%20A%20new%20look%20at%20an%20old%20topic,%20advances%20in%20laboratory%20diagnosis,%20and%20therapeutic%20strategies.%20Int%20J%20Health%20Sci.%202017;11(5):63%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Wasim M, Awan FR, Khan HN, Ayesha H. An overview of traditional and novel therapeutic options for the management of phenylketonuria. Crit Reviews™ Eukaryot Gene Expression. 2018;28(2):177–85.</cite> [<a href="https://doi.org/10.1615/CritRevEukaryotGeneExpr.2018023073" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30055544/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wasim%20M,%20Awan%20FR,%20Khan%20HN,%20Ayesha%20H.%20An%20overview%20of%20traditional%20and%20novel%20therapeutic%20options%20for%20the%20management%20of%20phenylketonuria.%20Crit%20Reviews%E2%84%A2%20Eukaryot%20Gene%20Expression.%202018;28(2):177%E2%80%9385." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Ney DM, Blank RD, Hansen KE. Advances in the nutritional and pharmacological management of phenylketonuria, Current Opinion in Clinical Nutrition and Metabolic Care (2013).</cite> [<a href="https://doi.org/10.1097/MCO.0000000000000002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4004170/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24136088/" class="usa-link">PubMed</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Mezzomo TR, Dias MRMG, Santos T, Pereira RM. Dietary intake in individuals with phenylketonuria: an integrative review. Nutrición Hospitalaria (2023).</cite> [<a href="https://doi.org/10.20960/nh.04579" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37705455/" class="usa-link">PubMed</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Inc BP. Palynziq (pegvaliase) [highlights of prescribing information]. 2020 (accessed 23 September 2022).</cite>
</li>
<li id="CR14">
<span class="label">14.</span><cite>Agency EM. Pegvaliase (Palynziq) [summary of product characteristics], 2022 (accessed 23 September 2022).</cite>
</li>
<li id="CR15">
<span class="label">15.</span><cite>Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, Harding CO, Bilder DA, Weng HH, Olbertz J, Merilainen M, Jiang J, Larimore K, Gupta S, Gu Z, Northrup H. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018;124(1):27–38.
</cite> [<a href="https://doi.org/10.1016/j.ymgme.2018.03.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29653686/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Thomas%20J,%20Levy%20H,%20Amato%20S,%20Vockley%20J,%20Zori%20R,%20Dimmock%20D,%20Harding%20CO,%20Bilder%20DA,%20Weng%20HH,%20Olbertz%20J,%20Merilainen%20M,%20Jiang%20J,%20Larimore%20K,%20Gupta%20S,%20Gu%20Z,%20Northrup%20H.%20Pegvaliase%20for%20the%20treatment%20of%20phenylketonuria:%20results%20of%20a%20long-term%20phase%203%20clinical%20trial%20program%20(PRISM).%20Mol%20Genet%20Metab.%202018;124(1):27%E2%80%9338." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Rohr F, Burton B, Dee A, Harding CO, Lilienstein J, Lindstrom K, MacLeod E, Rose S, Singh R, van Calcar S, Whitehall K. Evaluating change in diet with Pegvaliase treatment in adults with phenylketonuria: analysis of phase 3 clinical trial data. Mol Genet Metab 141(3) (2024).</cite> [<a href="https://doi.org/10.1016/j.ymgme.2023.108122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38184920/" class="usa-link">PubMed</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, Rice GM, Dorenbaum A, Neuenburg JK, Musson DG, Gu Z, Sile S. Single-dose, subcutaneous Recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014;384(9937):37–44.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(13)61841-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4447208/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24743000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Longo%20N,%20Harding%20CO,%20Burton%20BK,%20Grange%20DK,%20Vockley%20J,%20Wasserstein%20M,%20Rice%20GM,%20Dorenbaum%20A,%20Neuenburg%20JK,%20Musson%20DG,%20Gu%20Z,%20Sile%20S.%20Single-dose,%20subcutaneous%20Recombinant%20phenylalanine%20ammonia%20lyase%20conjugated%20with%20polyethylene%20glycol%20in%20adult%20patients%20with%20phenylketonuria:%20an%20open-label,%20multicentre,%20phase%201%20dose-escalation%20trial.%20Lancet.%202014;384(9937):37%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Zori R, Thomas JA, Shur N, Rizzo WB, Decker C, Rosen O, Li M, Schweighardt B, Larimore K, Longo N. Induction, titration, and maintenance dosing regimen in a phase 2 study of Pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Mol Genet Metab. 2018;125(3):217–27.
</cite> [<a href="https://doi.org/10.1016/j.ymgme.2018.06.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30146451/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zori%20R,%20Thomas%20JA,%20Shur%20N,%20Rizzo%20WB,%20Decker%20C,%20Rosen%20O,%20Li%20M,%20Schweighardt%20B,%20Larimore%20K,%20Longo%20N.%20Induction,%20titration,%20and%20maintenance%20dosing%20regimen%20in%20a%20phase%202%20study%20of%20Pegvaliase%20for%20control%20of%20blood%20phenylalanine%20in%20adults%20with%20phenylketonuria.%20Mol%20Genet%20Metab.%202018;125(3):217%E2%80%9327." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Harding CO, Amato RS, Stuy M, Longo N, Burton BK, Posner J, Weng HH, Merilainen M, Gu Z, Jiang J, Vockley J. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation phase 3 clinical trial. Mol Genet Metab. 2018;124(1):20–6.
</cite> [<a href="https://doi.org/10.1016/j.ymgme.2018.03.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29628378/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Harding%20CO,%20Amato%20RS,%20Stuy%20M,%20Longo%20N,%20Burton%20BK,%20Posner%20J,%20Weng%20HH,%20Merilainen%20M,%20Gu%20Z,%20Jiang%20J,%20Vockley%20J.%20Pegvaliase%20for%20the%20treatment%20of%20phenylketonuria:%20A%20pivotal,%20double-blind%20randomized%20discontinuation%20phase%203%20clinical%20trial.%20Mol%20Genet%20Metab.%202018;124(1):20%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med. 2011;171(6):591–3.
</cite> [<a href="https://doi.org/10.1001/archinternmed.2011.89" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21444854/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Weiss-Smith%20S,%20Deshpande%20G,%20Chung%20S,%20Gogolak%20V.%20The%20FDA%20drug%20safety%20surveillance%20program:%20adverse%20event%20reporting%20trends.%20Arch%20Intern%20Med.%202011;171(6):591%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803.
</cite> [<a href="https://doi.org/10.7150/ijms.6048" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3689877/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23794943/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sakaeda%20T,%20Tamon%20A,%20Kadoyama%20K,%20Okuno%20Y.%20Data%20mining%20of%20the%20public%20version%20of%20the%20FDA%20adverse%20event%20reporting%20system.%20Int%20J%20Med%20Sci.%202013;10(7):796%E2%80%93803." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Yin Y, Shu Y, Zhu J, Li F, Li J. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib. Sci Rep 12(1) (2022).</cite> [<a href="https://doi.org/10.1038/s41598-022-23834-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9664039/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36380085/" class="usa-link">PubMed</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Brown EG. Methods and pitfalls in searching drug safety databases utilising the medical dictionary for regulatory activities (MedDRA). Drug Saf. 2003;26(3):145–58.
</cite> [<a href="https://doi.org/10.2165/00002018-200326030-00002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12580645/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brown%20EG.%20Methods%20and%20pitfalls%20in%20searching%20drug%20safety%20databases%20utilising%20the%20medical%20dictionary%20for%20regulatory%20activities%20(MedDRA).%20Drug%20Saf.%202003;26(3):145%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Liu W, Du Q, Guo Z, Ye X, Liu J. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database. Front Pharmacol 14 (2023).</cite> [<a href="https://doi.org/10.3389/fphar.2023.1283247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10667432/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38027003/" class="usa-link">PubMed</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Burton BK, Clague GE, Harding CO, Kucuksayrac E, Levy DG, Lindstrom K, Longo N, Maillot F, Muntau AC, Rutsch F, Zori RT. Long-term comparative effectiveness of Pegvaliase versus medical nutrition therapy with and without Sapropterin in adults with phenylketonuria. Mol Genet Metab 141(1) (2024).</cite> [<a href="https://doi.org/10.1016/j.ymgme.2023.108114" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38142628/" class="usa-link">PubMed</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Alfadhel M, Albarakati R. First successful outcomes of Pegvaliase (PALYNZIQ) in children. BMC Med Genom 17(1) (2024).</cite> [<a href="https://doi.org/10.1186/s12920-024-01847-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10958957/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38515136/" class="usa-link">PubMed</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Longo N, Zori R, Wasserstein MP, Vockley J, Burton BK, Decker C, Li M, Lau K, Jiang J, Larimore K, Thomas JA. Long-term safety and efficacy of Pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study. Orphanet J Rare Dis 13(1) (2018).</cite> [<a href="https://doi.org/10.1186/s13023-018-0858-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6031112/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29973227/" class="usa-link">PubMed</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Harding CO, Longo N, Northrup H, Sacharow S, Singh R, Thomas JA, Vockley J, Zori RT, Bulloch Whitehall K, Lilienstein J, Lindstrom K, Levy DG, Jones S, Burton BK. Pegvaliase for the treatment of phenylketonuria: final results of a long-term phase 3 clinical trial program. Mol Genet Metabolism Rep 39 (2024).</cite> [<a href="https://doi.org/10.1016/j.ymgmr.2024.101084" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11061743/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38694233/" class="usa-link">PubMed</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Qi Y, Patel G, Henshaw J, Gupta S, Olbertz J, Larimore K, Harding CO, Merilainen M, Zori R, Longo N, Burton BK, Li M, Gu Z, Zoog SJ, Weng HH, Schweighardt B. Pharmacokinetic, pharmacodynamic, and Immunogenic rationale for optimal dosing of pegvaliase, a pegylated bacterial enzyme, in adult patients with phenylketonuria. Clin Transl Sci. 2021;14(5):1894–905.
</cite> [<a href="https://doi.org/10.1111/cts.13043" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8504851/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34057292/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qi%20Y,%20Patel%20G,%20Henshaw%20J,%20Gupta%20S,%20Olbertz%20J,%20Larimore%20K,%20Harding%20CO,%20Merilainen%20M,%20Zori%20R,%20Longo%20N,%20Burton%20BK,%20Li%20M,%20Gu%20Z,%20Zoog%20SJ,%20Weng%20HH,%20Schweighardt%20B.%20Pharmacokinetic,%20pharmacodynamic,%20and%20Immunogenic%20rationale%20for%20optimal%20dosing%20of%20pegvaliase,%20a%20pegylated%20bacterial%20enzyme,%20in%20adult%20patients%20with%20phenylketonuria.%20Clin%20Transl%20Sci.%202021;14(5):1894%E2%80%93905." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder DA, Burton B, Gross C, Northrup H, Rohr F, Sacharow S, Sanchez-Valle A, Stuy M, Thomas J, Vockley J, Zori R. Harding, Evidence- and consensus-based recommendations for the use of Pegvaliase in adults with phenylketonuria. Genet Sci. 2019;21(8):1851–67.</cite> [<a href="https://doi.org/10.1038/s41436-018-0403-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6752676/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30546086/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Longo%20N,%20Dimmock%20D,%20Levy%20H,%20Viau%20K,%20Bausell%20H,%20Bilder%20DA,%20Burton%20B,%20Gross%20C,%20Northrup%20H,%20Rohr%20F,%20Sacharow%20S,%20Sanchez-Valle%20A,%20Stuy%20M,%20Thomas%20J,%20Vockley%20J,%20Zori%20R.%20Harding,%20Evidence-%20and%20consensus-based%20recommendations%20for%20the%20use%20of%20Pegvaliase%20in%20adults%20with%20phenylketonuria.%20Genet%20Sci.%202019;21(8):1851%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Vucko ER, Havens KE, Baker JJ, Burton BK. Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower doses. Mol Genet Metabolism Rep 32 (2022).</cite> [<a href="https://doi.org/10.1016/j.ymgmr.2022.100905" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9421444/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36046394/" class="usa-link">PubMed</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Inc BP. Palynziq (pegvaliase) highlights of prescribing information, 2018 (accessed 20 September 2023).</cite>
</li>
<li id="CR33">
<span class="label">33.</span><cite>Brockow K, Schallmayer S, Beyer K, Biedermann T, Fischer J, Gebert N, Grosber M, Jakob T, Klimek L, Kugler C, Lange L, Pfaar O, Przybilla B, Rietschel E, Rueff F, Schnadt S, Szczepanski R, Worm M, Kupfer J, Gieler U, Ring J. Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis. Allergy. 2015;70(2):227–35.
</cite> [<a href="https://doi.org/10.1111/all.12548" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25407693/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brockow%20K,%20Schallmayer%20S,%20Beyer%20K,%20Biedermann%20T,%20Fischer%20J,%20Gebert%20N,%20Grosber%20M,%20Jakob%20T,%20Klimek%20L,%20Kugler%20C,%20Lange%20L,%20Pfaar%20O,%20Przybilla%20B,%20Rietschel%20E,%20Rueff%20F,%20Schnadt%20S,%20Szczepanski%20R,%20Worm%20M,%20Kupfer%20J,%20Gieler%20U,%20Ring%20J.%20Effects%20of%20a%20structured%20educational%20intervention%20on%20knowledge%20and%20emergency%20management%20in%20patients%20at%20risk%20for%20anaphylaxis.%20Allergy.%202015;70(2):227%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Salter SM, Vale S, Sanfilippo FM, Loh R, Clifford RM. Long-term effectiveness of online anaphylaxis education for pharmacists. Am J Pharm Educ. 2014;78(7):136.
</cite> [<a href="https://doi.org/10.5688/ajpe787136" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4174378/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25258441/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Salter%20SM,%20Vale%20S,%20Sanfilippo%20FM,%20Loh%20R,%20Clifford%20RM.%20Long-term%20effectiveness%20of%20online%20anaphylaxis%20education%20for%20pharmacists.%20Am%20J%20Pharm%20Educ.%202014;78(7):136." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Patrawala M, Kuruvilla M, Li H. Successful desensitization of Pegvaliase (Palynziq<sup>®</sup>) in a patient with phenylketonuria. Mol Genet Metabolism Rep 23 (2020).</cite> [<a href="https://doi.org/10.1016/j.ymgmr.2020.100575" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7063228/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32181140/" class="usa-link">PubMed</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12181874/bin/13023_2025_3864_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (699.4KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data are available on the FAERS database.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Orphanet Journal of Rare Diseases are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s13023-025-03864-4"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/13023_2025_Article_3864.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.6 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12181874/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12181874/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12181874%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12181874/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12181874/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12181874/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40542371/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12181874/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40542371/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12181874/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12181874/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="RFUO0XLHuQIe66NeFsIn3W8uZAS2Wc0F6MQpTHM5ffuS4XZ4HVynBDevCX0mzD6C">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-B7-tgZZA.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-BLbQGH8u.js"></script>
    
    

    </body>
</html>
